All In Biotech

Drug Trial Radar · NCT06121011

A Global Prospective Observational Registry of Patients With Pompe Disease

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Feb 16, 2024

Primary completion

Dec 20, 2034

Study completion Dec 20, 2034

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate. The objectives of the registry are: * To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)/serious adverse events (SAEs) occurring in Pompe disease patients * To evaluate the long-term real-world effectiveness of Pompe disease treatments * To evaluate the long-term real-world impact of Pompe disease treatments on quality of life (QOL) and patient-reported outcomes (PROs) * To describe the natural history of untreated Pompe disease

Conditions

  • Pompe Disease

Interventions

  • Cipaglucosidase alfaBiological

    Enzyme Replacement Therapy (ERT) via intravenous infusion

  • MiglustatDrug

    Participants received ATB200 co-administered with AT2221 (Miglustat)

  • Alglucosidase alfa or Avalglucosidase alfaBiological

    Patients prescribed other commercially available ERT after local regulatory approval

  • UntreatedOther

    Patients who are not currently receiving any medical therapy for Pompe disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate long-term safety of Pompe disease treatmentsTime frame: 5 years

Locations

41 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Arkansas Medical Science

    Little Rock, Arkansas · Recruiting

  • University of California Irvine

    Irvine, California · Recruiting

  • Wolfson Children's Hospital

    Jacksonville, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Indiana University, IU Health Physicians Neurology

    Indianapolis, Indiana · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • NYU Neurogenetics, NYU Langone Medical Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Cincinnati Children's Hospital

    Cincinnati, Ohio · Recruiting

  • University of Pennsylvania Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia · Recruiting

  • Medizinische Universitaet Wien

    Vienna, Austria · Not yet recruiting

  • Laboratory for Muscle Diseases and Neuropathies

    Leuven, Belgium · Recruiting

  • Aarhus Universitets hospital

    Aarhus C, Denmark · Recruiting

  • Ruhr-Universität Bochum im St. Josef-Hospital

    Bochum, Germany · Recruiting

  • SphinCS, Institute of Clinical Science in LSD

    Höchheim, Germany · Recruiting

  • Universitätsklinikum Gießen und Marburg GmhH

    Marburg, Germany · Recruiting

  • Universitat Munchen - Friedrich Baur Institut

    München, Germany · Recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Not yet recruiting

  • Eginition Hospital

    Athens, Greece · Not yet recruiting

  • University of Pécs

    Pécs, Hungary · Not yet recruiting

  • University of Szeged, Szent-Györgyi Albert Clinical Center

    Szeged, Hungary · Not yet recruiting

  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

    Bari, Italy · Not yet recruiting

  • Centre of Expertise for muscular diseases and peripheral neuropathies European Reference Network for Rare Neuromuscular Diseases

    Naples, Italy · Not yet recruiting

  • Department of Neurosciences Rita Levi Montalcini, University of Torino

    Torino, Italy · Not yet recruiting

  • Regional Coordinating Centre for Rare Diseases, university Hospital of Udine, Udine, Italy

    Udine, Italy · Not yet recruiting

  • Dept of Pediatrics Erasmus MC - Sophia Children's Hospital

    Rotterdam, Netherlands · Not yet recruiting

  • entrum Medyczne Medyk

    Rzeszów, Poland · Not yet recruiting

  • University Medical Centre Ljubljana, Institute of Clinical Neurophysiology

    Ljubljana, Slovenia · Not yet recruiting

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom · Recruiting

  • Cambridge University - Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • University Hospital of Wales, Cardiff

    Cardiff, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Recruiting

  • National Hospital for Neurology and Neurosurgery

    London, United Kingdom · Recruiting

  • Great Ormond Street Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Royal Free Hospital NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.